Navigation Links
Scientists pinpoint protein that could improve small cell lung cancer therapies

Approximately 15 percent of all lung cancers are small cell lung cancers (SCLC), which grow rapidly and often develop resistance to chemotherapy. However, researchers at Virginia Commonwealth University Massey Cancer Center have revealed new insights into the mechanisms leading to this resistance that may lead to improved therapies.

Chemotherapies work primarily by mediating B-cell lymphoma 2 (Bcl-2) family proteins, which are responsible for regulating cell death. Depending on their function, this family of proteins can trigger a form of cell suicide known as apoptosis or they can activate mechanisms that prevent apoptosis and promote cell survival. Recently, drugs have been developed that block the function of pro-survival Bcl-2 family proteins. One of these drugs known as ABT-737, and its orally available derivative ABT-263 (currently being tested in clinical trials), has been shown to kill SCLC cells and potentially increase the effectiveness of chemotherapies that affect Bcl-2 family proteins. However, the effectiveness of ABT-737 varies greatly in a broad range of SCLC cells.

In a recent study published in Nature Publishing Group's journal Cell Death & Disease, Massey researchers Hisashi Harada, Ph.D., and Geoffrey Krystal, M.D., Ph.D., discovered that the expression of a protein called Noxa is critical to the effectiveness of ABT-737 because it helps regulate the function of MCL-1, another pro-survival Bcl-2 family protein. Through experiments with cultured SCLC cells, the researchers found that Noxa recruits MCL-1 to the mitochondria, the cell's power producer, which degrades MCL-1 and makes the cancer cells more sensitive to ABT-737.

"Essentially, we discovered how ABT-737 works and why some small cell lung cancer cells are not as affected by it," says Harada, member of the Cancer Cell Signaling research program at Massey and assistant professor in the Philips Institute of Oral and Craniofacial Molecular Biology at the VCU School of Dentistry. "By targeting Noxa, which breaks down MCL-1, we could potentially develop novel small cell lung cancer therapies and help overcome resistance to conventional chemotherapies."

Previous research has shown that Bcl-2 pro-survival family members, like BCL-2 and MCL-1, are over-expressed in SCLC. However, until recently the precise role of these proteins in SCLC biology and therapeutic resistance was poorly understood. When ABT-737 was discovered, it was able to block BCL-2 and another pro-survival protein known as BCL-XL, but not MCL-1. The current research points to the pro-survival functions of MCL-1 as the cause of ABT-737's varied effectiveness.

"Now that we have uncovered Noxa and MCL-1 as potential targets, we can work to better define the mechanisms that help regulate their expression," says Krystal, member of the Developmental Therapeutics research program at Massey, professor of internal medicine in the Division of Hematology, Oncology and Palliative Care and affiliate professor in the Department of Microbiology and Immunology in the VCU School of Medicine, and chair of the Division of Hematology/Oncology at the Hunter Holmes McGuire VA Medical Center. "Moving forward, we plan to conduct additional studies to further define these mechanisms in order to better sensitize small cell lung cancer cells to drugs like ABT-737."


Contact: Alaina Schneider
Virginia Commonwealth University

Related medicine news :

1. Scientists solving the mystery of human consciousness
2. Scientists uncover multiple faces of deadly breast cancer
3. Scientists identify major source of cells defense against oxidative stress
4. Scientists tailor cell surface targeting system to hit organelle ZIP codes
5. Scientists rewrite rulebook on breast cancer in landmark global study
6. Warwick scientists uncover how checkpoint proteins bind chromosomes
7. NIH scientists link quickly spreading gene to Asian MRSA epidemic
8. Joslin scientists identify important mechanism that affects the aging process
9. Scripps Research scientists show how memory B cells stay in class to fight different infections
10. Scientists Map Melanomas Genome
11. A*STAR scientists discover switch to boost anti-viral response to fight infectious diseases
Post Your Comments:
Related Image:
Scientists pinpoint protein that could improve small cell lung cancer therapies
(Date:11/30/2015)... Minneapolis, MN (PRWEB) , ... November 30, 2015 ... ... launched at . The directory is specialized and only includes chiropractic ... is to find a competent and trustworthy alternative health practitioner when back pain ...
(Date:11/30/2015)... ... November 30, 2015 , ... ... vehicle experience this summer, ushering in a new era of publicly accessible automated ... electric shuttle, will continue to offer guests an up-close look at the shuttle ...
(Date:11/30/2015)... ... 2015 , ... In an effort to provide local families ... Christian Church of Flint, MI, hosted a family-oriented evening themed on “Candy Land”, ... candy dubbed “Candy Mountain”. , A Forever Recovery, a holistic treatment center for ...
(Date:11/30/2015)... ... November 30, 2015 , ... In an effort to ... to access life-saving information provided directly from top experts in mesothelioma, in 2016 ... conferences in three major cities: Houston, San Francisco, and Chicago. , “For ...
(Date:11/30/2015)... VA (PRWEB) , ... November 30, 2015 , ... ... Foundation kicked off its annual fundraising campaign to raise funds for its research, ... raises approximately 10% of the organization’s annual funding. , The Mesothelioma Applied Research ...
Breaking Medicine News(10 mins):
(Date:11/30/2015)... Die MEDTEC Japan 2016, ... Entwicklung und Herstellung medizinischer Geräte, findet ... in Tokyo ... Foto: ... --> ...
(Date:11/30/2015)... India , December 1, 2015 /PRNewswire/ ... --> adds "Endometriosis - Pipeline ... provides an overview on therapeutic pipeline of ... to create effective counter strategies to gain ... identifying new targets and MOAs to produce ...
(Date:11/30/2015)... Nevro Corp. (NYSE: NVRO ), a global ... the treatment of chronic pain, today announced that the Patent ... Trademark Office (USPTO) has denied instituting an inter partes ... patent).  --> --> ... filed two petitions challenging the validity of certain claims of ...
Breaking Medicine Technology: